Abstract Glucocorticoid (GC) excess causes a great increase in fracture risk, but the effects of GC excess on cortical bone geometry are unknown. The present study was performed to examine the effects of GC excess on cortical bone geometry in both premenopausal and postmenopausal women. Ninety-six women receiving oral GC treatments and 10 women with Cushing syndrome (CS) were each compared to age-matched control subjects using peripheral quantitative computed tomography. Total area, periosteal circumference, and polar strength strain index (SSIp) were significantly lower in GC-treated patients compared with control subjects in premenopausal women but not in postmenopausal women. Moreover, cortical area and thickness as well as periosteal circumference and SSIp were significantly lower in patients with CS compared to controls in premenopausal women but not in postmenopausal women. Total area, cortical area, cortical thickness, periosteal circumference, as well as SSIp were significantly lower in GC-treated patients with vertebral fractures compared to those without vertebral fractures in premenopausal women but not in postmenopausal women. In conclusion, endogenous or exogenous GC excess affects bone geometry of forearms of premenopausal, but not postmenopausal, women. These effects of GC excess on bone geometry may provide a strength loss mechanism beneath increased vertebral fracture risk.
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Keywords Glucocorticoid Á Cushing syndrome Á Fracture Á Bone geometry Glucocorticoids (GCs) are used for the treatment of various serious diseases of autoimmune, neurological, dermatological, and respiratory origin. GC-induced osteoporosis (GIO) is a serious problem for patients taking GC therapy, and many patients suffer from decreases in quality of life and reduced ability to conduct activities of daily life. GC administration causes bone loss and an increase in bone fragility, resulting in a great increase in fracture risk [1] [2] [3] [4] [5] [6] . Approximately 50% of patients with Cushing syndrome (CS) or patients taking long-term GC have fragility fractures [3, 4, 7, 8] . Excessive intrinsic GC due to CS is associated with increased bone resorption markers, decreased bone mineral density (BMD), and increased fracture risk [7] [8] [9] [10] [11] [12] [13] . However, a meta-analysis of prior GC use and fracture risk suggested that fracture risk was only partly explained by BMD [4] . Moreover, the thresholds of BMD for vertebral fractures were higher in patients with oral GC treatment [14, 15] . These findings indicate that BMD differences may not adequately explain fracture risk in patients with GC excess.
Bone strength is determined by bone structural dimensions and by the limiting properties of the bone tissue. The latter may be influenced by accumulated microdamage, bone turnover effects, anomalies of bone matrix proteins, and degree of mineralization [16] . Peripheral quantitative computed tomography (pQCT) has the potential to measure volumetric BMD and the advantage of distinguishing trabecular from cortical bones. More importantly, it can measure geometric properties of long bones, such as area and circumference of total bone as well as cortical area and cortical thickness [17] . Moreover, pQCT helps to estimate bone strength by calculating polar strength strain index (SSIp), which has recently been shown to predict bone strength noninvasively [18] . Bone size increases with aging [19] . Increased bone loss after menopause is associated with increased rates of periosteal apposition [20] . Our previous study revealed that both excess and deficiencies of endogenous parathyroid hormone (PTH) affect bone geometry determined by pQCT [21] . Moreover, age, grip strength, and smoking affected forearm bone geometry in pQCT [22, 23] . These findings suggest that bone geometric changes are useful in evaluating mechanisms of bone fragility. Although several studies reported that a decrease in cortical BMD is associated with fracture risk in GIO [24, 25] , the effects of GC excess on cortical bone geometry remain unclear at the present time.
The present study employed pQCT to examine the effects of GC excess on cortical bone geometry in female patients receiving oral GC treatments or patients with CS. Moreover, the influences of GC excess on bone geometry were analyzed by separating the groups with and without menstruation.
Subjects and Methods

Subjects
To assess the effect of exogenous GC excess on bone geometry, 96 female patients who were treated with oral GC (5 mg/day and more of prednisolone) for more than 6 months participated in this study. Among these patients, 48 were premenopausal and 48 were postmenopausal. Premenopausal women had menses with normal cycle at the study point and had not used hormonal contraceptives. Basal diseases of GC-treated patients are shown in Table 1 .
We excluded those subjects whose activities of daily life were diminished by medical review and physical examination. Among the 96 patients, 62 (64.6 %) had autoimmune diseases. Patients with rheumatoid arthritis or those being treated with bisphosphonates were excluded from the study. Control subjects were Japanese women who visited our outpatient clinic in order to determine whether or not they might suffer from osteoporosis or who were recruited as normal volunteers. They were age-and body size-matched with premenopausal and postmenopausal GC patients, respectively.
To assess the effects of endogenous GC excess on bone geometry, 10 patients (four premenopausal and six postmenopausal women) with CS before treatment participated in this study. CS was diagnosed by clinical features, increased excretion of urinary free cortisol, inappropriate suppression of serum cortisol by low-dose dexamethasone suppression test, and lack of physiological circadian rhythm of serum cortisol. Control subjects were Japanese women who visited our outpatient clinic in order to determine whether or not they might suffer from osteoporosis or who were recruited as normal volunteers matched by age, body size, and menstrual status.
The study was approved by the ethical review board of Kobe University Hospital. All subjects agreed to participate in the study and gave informed consent.
Radiography
Lateral radiographs of the thoracic and lumbar spine were taken. The anterior, central, and posterior heights of each of the 13 vertebral bodies from T4 to L4 were measured using an electronic caliper. Vertebral fractures were considered to be present if at least one of three height measurements taken along the length of the same vertebra was decreased by more than 20% compared with the height of the nearest uncompressed vertebral body. Determing vertebral fracture from radiographs of the lumbar spine is difficult due to a type of vertebral deformity that corresponds to fractures. Definitions of vertebral fractures with high true positive rates and low false positive rates are clinically useful in identifying women who may have vertebral fractures. The criterion in the present study ([20%) was considered to be good for the definition of vertebral fractures [26] .
BMD Measurements by pQCT
pQCT analysis was performed at the nondominant forearm using an XCT-960 device (Stratec, Pforzheim, Germany) with a single-energy X-ray source, as previously described [27] . All CT scans were acquired with a slice thickness of 2.5 mm and a pixel size of 0.59 mm. The scanner was positioned at the site of the forearm whose distance from the ulnar styloid process corresponded to 4 and 20% of forearm length for distal radius and midradius, respectively. To calculate the structural properties of the cortical shell, trabecular and cortical bone were separated. To separate cortical bone, all voxels (0.295 x 0.295 x 1 mm 3 ) of the scanned image with a BMD lower than a threshold of 267 mg/cm 3 were eliminated [28] . To separate trabecular bone, 55% of the cross-sectional area of bone was peeled off from the outer area. BMD was calculated for cortical and trabecular bone separately. Total and trabecular BMD were measured at the distal radius. Cortical BMD and bone geometric indices were measured at midradius. Cortical area is the region with linear attenuation. Cortical thickness was defined as the mean distance between the inner and outer edges of the cortical shell. SSIp is an index of mechanical resistance to bending or torsion. SSIp was calculated by (r 2 x A x CD/1,200)/r max , where A is the area of a voxel (mm 2 ), r is its distance from the center of gravity, CD is the cortical density (mg/mm 3 ) and is divided by the normal physiological density of cortical bone (1,200 mg/mm 3 ), and r max is the maximum distance of a voxel from the center of gravity [29] . The coefficient of variation was \1%.
Statistical Analysis
All data were expressed as the mean ± standard deviation (SD) for each index. A regression analysis was performed using the statistical computer program StatView (Abacus Concepts, Berkley, CA). Simple regression analysis was used to assess the linear relationship between study parameters, and Pearson's correlation coefficients were calculated. Comparisons between affected and control groups were made with the nonparametric Mann-Whitney U-test. P \ 0.05 was considered significant.
Results
Background Data
Baseline indices are shown in Table 2 in premenopausal and postmenopausal women treated with GC and corresponding age-matched control subjects. Numbers of patients with vertebral fractures were 7 and 18 among premenopausal and postmenopausal women treated with GC, respectively. Body height, body weight, and body mass index (BMI) were similar between controls and GCtreated patients among both premenopausal and postmenopausal women. Baseline indices are shown in Table 3 in premenopausal and postmenopausal women with CS and each age-matched control. Control subjects were also matched with body height and BMI, and there were no significant differences in body weight between control and CS patients in both premenopausal and postmenopausal groups.
Comparisons Between Women on GC Treatment and Age-matched Controls
We compared various indices between controls and GCtreated patients among both premenopausal and postmenopausal women (Table 4) . Total BMD as well as trabecular and cortical BMD were not different between controls and GC-treated patients in both premenopausal and postmenopausal groups. As for bone geometry indices, total area, periosteal circumferences, and SSIp were significantly lower in GC-treated patients compared with control subjects in the premenopausal group. In postmenopausal women, cortical area and SSIp were significantly higher in GC-treated patients compared with control subjects, although its significance is unknown. Grip strength was not significantly related to any pQCT parameters in postmenopausal women treated with GC (data not shown). However, in premenopausal women treated with GC, grip strength was significantly related to total and trabecular BMD, cortical area, and cortical thickness (r = 0.533, P = 0.0001; r = 0.489, P = 0.0005; r = 0.313, P = 0.0358; r = 0.389, P = 0.0078, respectively), although it was not significantly related to cortical BMD, total area, periosteal and endocortical circumferences, and SSIp (data not shown). These findings suggest that grip strength modulated the effect of GC on pQCT parameters in premenopausal women.
Comparisons of CS and Age-matched Controls
Various indices were compared by pQCT between patients with CS and age-matched control subjects in the premenopausal and postmenopausal groups (Table 5) . Total BMD and cortical BMD were significantly lower in patients with CS compared with controls in premenopausal, but not in postmenopausal, women. As for bone geometry indices, cortical area and thickness, periosteal circumference, and SSIp were significantly lower in patients with CS compared with controls in premenopausal, but not in postmenopausal, women. Endocortical circumferences were similar between controls and CS patients in both premenopausal and postmenopausal women.
Comparison of Various Indices by pQCT Between GCTreated Women with and Without Vertebral Fractures
Various indices were compared by pQCT between GCtreated women with and without vertebral fractures (Table 6 ). Total and trabecular BMD were significantly lower in GC-treated patients with vertebral fractures compared to those without vertebral fractures in premenopausal, but not in postmenopausal, women. Total area, cortical area, cortical thickness, periosteal circumference, as well as SSIp were significantly lower in GCtreated patients with vertebral fractures compared to those without vertebral fractures in premenopausal, but not in postmenopausal, women. Endocortical circumferences were similar between GC-treated patients with and without vertebral fractures in both premenopausal and postmenopausal women.
Effects of GC Treatment Details in Premenopausal Women
GC administration was associated with a significant change in bone geometry in premenopausal women. We therefore examined the correlation coefficients between bone geometry indices by pQCT and GC treatment in premenopausal women (Table 7) . Only duration of GC treatment, but not the present dose or the maximum dose, was significantly correlated with cortical area, cortical thickness, and periosteal circumference, which were significantly affected by GC excess and related to the presence of vertebral fractures in premenopausal women.
Correlations Between BMD and Cortical Thickness or Area in Women with and Without GC Treatment
We examined the relationships between BMD and cortical thickness or area in women with and without GC treatment.
As shown in Table 8 , cortical thickness and area were correlated with BMD parameters in women with and without GC treatment in both the premenopausal and postmenopausal groups. However, the relationships between cortical area and trabecular or cortical BMD seemed lower in premenopausal women compared with those in postmenopausal women.
Discussion
To our knowledge, the relationship between GC administration and bone geometry has not been previously studied in humans. In studies on other animals, GC administration resulted in a decreased periosteal mineralizing surface in rats [30] and the longitudinal axes of vertebrae and lengths of femurs were smaller in GC-treated minipigs [31] . These findings raise the possibilities that GC administration might reduce bone size in growing animals and might affect bone geometry. In the present study, total bone area, periosteal circumference, and SSIp were significantly lower in GCtreated patients compared with matched controls in premenopausal, but not in postmenopausal, women. Moreover, total bone area, periosteal circumference, and SSIp were significantly lower in GC-treated patients with vertebral fractures compared to those without vertebral fractures in premenopausal women. These findings suggest that the strength loss and increased fracture risk in patients with GC treatment are evident in the geometry. Therefore, the disruption of the adapted change of bone geometry by GC might partly augment a decrease in bone strength induced by low BMD. A long-term and continuous pattern of GC use resulted in an increased risk of hip and vertebral fracture [4, [32] [33] [34] . The number of collapsed vertebral bodies was significantly correlated to age at disease onset, disease duration, and urinary free cortisol levels at disease diagnosis in patients with long-term cure of CS [35] . In several studies, the daily dose of GC was shown to predict fractures [2, 6] . In the present study, duration of treatment was significantly related to reduced cortical area and thickness as well as to smaller periosteal circumferences in premenopausal women, although these parameters were not significantly correlated with current or maximum dose level. These findings suggest that duration of GC use might affect fracture risk by affecting bone geometry in premenopausal women with GC treatment. Subjects in our study predominantly suffered autoimmune diseases with relatively small differences in daily dose of GC. This may be why we were unable to detect a dose level effect on geometry.
Endogenous GC excess exerts negative effects on bone in patients with CS. Bone formation and resorption markers were decreased and increased in CS, respectively [11, 12] . As for BMD, lumbar spine BMD, which is rich in trabecular bone, is generally decreased in most patients with CS [9, 10] . Decreased BMD was reported in studies using pQCT [36] . Moreover, several studies have indicated that fracture risk is increased in CS [7, 8, 13] . In the present study, total bone area, periosteal circumference, and SSIp were significantly lower in patients with CS compared to controls in premenopausal, but not in postmenopausal, women. These findings suggest that bone geometry is changed in patients with CS and that endogenous GC excess affects bone geometry in a manner similar to exogenous GC administration. The negative effect of GC on bone formation may be crucial in the pathogenesis of GIO, although the mechanism of GC-inhibited bone formation is not fully elucidated [37] . GC-inhibited bone formation might result in reduced periosteal circumferences, although how GC excess influences bone formation on endocortical and periosteal surfaces is still unknown. Reduced sex steroid hormones are also related to GIO. However, sex hormone deficiency does not seem to be related to GC-induced change of bone geometry in the present study since those changes were greater in presumably estrogen-replete premenopausal women. On the other hand, secondary hyperparathyroidism might be induced in GIO. However, PTH affects bone geometry by increasing periosteal circumferences [38] , which is contrary to the effects of bone geometry by GC excess in the present study [21] . Alternatively, as a consequence of the catabolic action of GC on protein metabolism, patients with CS possess myopathy with muscle weakness, which might lead to bone loss by reducing the mechanical stimulus on bone induced by muscle contraction [8] . It is therefore possible that GC excess decreases periosteal circumferences by reducing muscle mechanical tension. The resistance to flexion of a cylinder is strengthened by increasing its external diameter. An increase in cortical thickness also reinforces bone strength. The biomechanical failure force of the long bone is correlated with the cortical bone thickness, cross-sectional area, and peripheral area moments of inertia (architectural indices of bone rigidity) but not with bone mineral content [39, 40] . Moreover, architectural properties of cortical bone were effective at predicting vertebral fractures in postmenopausal women [41, 42] . BMD is decreased predominantly at trabecular bone in GIO and CS. However, several studies have indicated that cortical factors are also affected and related to vertebral fractures by GC excess [24, 25] . These findings indicate that GC excess affects cortical bone as well as trabecular bone. In the present study, there were no significant differences in any cortical parameters between groups with and without vertebral fractures in postmenopausal GC-treated patients. In contrast, in premenopausal patients, total bone area, periosteal circumference, cortical area, cortical thickness, and SSIp were significantly lower in GC-treated patients with vertebral fractures compared to those without vertebral fractures. These findings suggest that the altered cortical factors are related to the decreased bone strength in patients with GC treatment, at least in premenopausal women.
Estrogen state affects bone metabolism and BMD. Several studies have examined the effects of GC excess on bone metabolism in either premenopausal or postmenopausal women [36, [43] [44] [45] . Karavitaki et al. [43] reported that bone loss is less profound in the peripheral skeleton of premenopausal female patients than in newly diagnosed patients with CS, although a previous study showed that young/adolescent patients on GC therapy can lose bone mass more rapidly than older patients [46] . In the present study, the changes of bone geometry by GC excess were observed in premenopausal, but not in postmenopausal, patients. In adulthood, total cross-sectional area and periosteal circumference increase with aging. Moreover, the apparent rate of endocortical bone resorption is greater than that of periosteal apposition. Consequently, cortical area decreases with aging, especially in postmenopausal women [23, 41, 47, 48] . Increased bone loss after menopause is associated with increased periosteal apposition rate [20] . These findings suggest that periosteal bone formation enhanced by estrogen withdrawal reverses the decrease of periosteal circumference in GC excess. Moreover, estrogen may make GC-induced effects on bone geometry more evident by suppressing the mechanical load response on the periosteal surface of long bones in premenopausal women since endogenous estrogen inhibits periosteal bone apposition in response to mechanical loading [49, 50] . Alternatively, GC excess affects potently higher metabolic bone, such as trabecular bone. Several reports suggest that bone turnover is high in premenopausal women [44, 45] , and rapid bone loss is observed after GC treatment in young women [46] . Therefore, bone metabolism might be easily influenced by GC excess in premenopausal compared with postmenopausal women, resulting in significant changes of bone geometry in young women. The relationships between cortical area and trabecular or cortical BMD seemed lower in premenopausal women compared with those in postmenopausal women with and without GC treatment in the present study. We can therefore speculate that cortical bone geometry is affected by some factors other than BMD in premenopausal women, which might be easily modulated by GC treatment.
In the present study, vertebral fractures were more frequent in postmenopausal women than in premenopausal women. Although the present study suggested that GCinduced bone geometry change is important for reduced bone strength in premenopausal, but not in postmenopausal, women, GC might potently affect BMD and quality of vertebral bone in postmenopausal women. Moreover, bone geometry change might play a less important role for the strength of vertebral bone compared to its role in forearm bone.
The present study has some limitations. First, our sample size was not large enough to make definitive conclusions. Second, since the subjects employed in the present study included many patients with autoimmune diseases, the nature of causal diseases for GC treatment might independently increase risk of vertebral fractures as well as influence bone geometry and fracture risk.
In conclusion, the present study showed that endogenous and exogenous GC excess affects forearm bone geometry in premenopausal, but not postmenopausal, women. In GCtreated or CS premenopausal women, cortical area and periosteal circumference were decreased, which might be related to vertebral fracture risk.
